Works by Girish, Sandhya
Results: 56
Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy.
- Published in:
- Cancer Reports, 2022, v. 5, n. 10, p. 1, doi. 10.1002/cnr2.1578
- By:
- Publication type:
- Article
Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
- Published in:
- Journal of Pharmacy & Pharmacology, 2001, v. 53, n. 7, p. 987, doi. 10.1211/0022357011776234
- By:
- Publication type:
- Article
Contradistinction between doxorubicin and epirubicin: in-vitro interaction with blood components.
- Published in:
- Journal of Pharmacy & Pharmacology, 2001, v. 53, n. 6, p. 815, doi. 10.1211/0022357011776162
- By:
- Publication type:
- Article
PHARMACOKINETICS INFORMS REMDESIVIR DOSING FOR PATIENTS WITH SEVERE RENAL IMPAIRMENT.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 201
- By:
- Publication type:
- Article
POPULATION PK ANALYSIS TO GUIDE DOSING WINDOW FOLLOWING LENACAPAVIR SC ADMINISTRATION.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 198
- By:
- Publication type:
- Article
Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer.
- Published in:
- Journal of Clinical Pharmacology, 2012, v. 52, n. 5, p. 691, doi. 10.1177/0091270011403742
- By:
- Publication type:
- Article
Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 11, p. 2276, doi. 10.1111/cts.13627
- By:
- Publication type:
- Article
Integrating real‐world data to accelerate and guide drug development: A clinical pharmacology perspective.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 10, p. 2293, doi. 10.1111/cts.13379
- By:
- Publication type:
- Article
Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 8, p. 1818, doi. 10.1111/cts.13312
- By:
- Publication type:
- Article
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1).
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 1, p. 130, doi. 10.1111/cts.13127
- By:
- Publication type:
- Article
Collaborations between Clinical Pharmacologists in Japan and in the United States ‐ Report from the IQ CPLG and JPMA CPTF Meeting in Tokyo, Japan.
- Published in:
- CTS: Clinical & Translational Science, 2021, v. 14, n. 1, p. 102, doi. 10.1111/cts.12853
- By:
- Publication type:
- Article
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 23, p. 5733, doi. 10.1002/cncr.27622
- By:
- Publication type:
- Article
Prediction of Human Pharmacokinetics of Antibody–Drug Conjugates From Nonclinical Data.
- Published in:
- CTS: Clinical & Translational Science, 2019, v. 12, n. 5, p. 534, doi. 10.1111/cts.12649
- By:
- Publication type:
- Article
Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
- Published in:
- Journal of Pharmacokinetics & Pharmacodynamics, 2017, v. 44, n. 6, p. 537, doi. 10.1007/s10928-017-9544-y
- By:
- Publication type:
- Article
Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2020, v. 9, n. 1, p. 48, doi. 10.1002/psp4.12482
- By:
- Publication type:
- Article
Time‐to‐Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine‐Citrulline‐Monomethylauristatin E Antibody–Drug Conjugates.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2019, v. 8, n. 8, p. 606, doi. 10.1002/psp4.12442
- By:
- Publication type:
- Article
AAPS Workshop Report: Strategies to Address Therapeutic Protein-Drug Interactions during Clinical Development.
- Published in:
- 2011
- By:
- Publication type:
- Report
Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 5, p. 669, doi. 10.1007/s40262-024-01366-3
- By:
- Publication type:
- Article
Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates.
- Published in:
- Clinical Pharmacokinetics, 2015, v. 54, n. 1, p. 81, doi. 10.1007/s40262-014-0182-x
- By:
- Publication type:
- Article
An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer.
- Published in:
- Clinical Pharmacokinetics, 2013, v. 52, n. 8, p. 657, doi. 10.1007/s40262-013-0060-y
- By:
- Publication type:
- Article
Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
- Published in:
- Leukemia & Lymphoma, 2020, v. 61, n. 12, p. 2905, doi. 10.1080/10428194.2020.1795154
- By:
- Publication type:
- Article
Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
- Published in:
- Leukemia & Lymphoma, 2020, v. 61, n. 1, p. 56, doi. 10.1080/10428194.2019.1657575
- By:
- Publication type:
- Article
Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2021, v. 88, n. 3, p. 499, doi. 10.1007/s00280-021-04296-0
- By:
- Publication type:
- Article
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2020, v. 86, n. 3, p. 347, doi. 10.1007/s00280-020-04119-8
- By:
- Publication type:
- Article
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
- Published in:
- 2018
- By:
- Publication type:
- journal article
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
- Published in:
- 2017
- By:
- Publication type:
- journal article
Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Population pharmacokinetics of bevacizumab in cancer patients with external validation.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 74, n. 2, p. 399, doi. 10.1007/s00280-014-2500-2
- By:
- Publication type:
- Article
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 4, p. 591, doi. 10.1007/s00280-012-1934-7
- By:
- Publication type:
- Article
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 5, p. 1229, doi. 10.1007/s00280-011-1817-3
- By:
- Publication type:
- Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology.
- Published in:
- British Journal of Clinical Pharmacology, 2021, v. 87, n. 6, p. 2493, doi. 10.1111/bcp.14662
- By:
- Publication type:
- Article
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
- Published in:
- British Journal of Clinical Pharmacology, 2017, v. 83, n. 12, p. 2767, doi. 10.1111/bcp.13381
- By:
- Publication type:
- Article
Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 2, p. 144, doi. 10.1002/cpdd.847
- By:
- Publication type:
- Article
Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics.
- Published in:
- Journal of Clinical Pharmacology, 2021, v. 61, n. 8, p. 1096, doi. 10.1002/jcph.1855
- By:
- Publication type:
- Article
Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, p. S105, doi. 10.1002/jcph.1720
- By:
- Publication type:
- Article
Physiologically Based Pharmacokinetic Model‐Informed Drug Development for Polatuzumab Vedotin: Label for Drug‐Drug Interactions Without Dedicated Clinical Trials.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, p. S120, doi. 10.1002/jcph.1718
- By:
- Publication type:
- Article
Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, p. S105, doi. 10.1002/jcph.1720
- By:
- Publication type:
- Article
Physiologically Based Pharmacokinetic Model‐Informed Drug Development for Polatuzumab Vedotin: Label for Drug‐Drug Interactions Without Dedicated Clinical Trials.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, p. S120, doi. 10.1002/jcph.1718
- By:
- Publication type:
- Article
Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies.
- Published in:
- 2020
- By:
- Publication type:
- Report